See more : Astrea Acquisition Corp. (ASAXW) Income Statement Analysis – Financial Results
Complete financial analysis of Summit Healthcare Acquisition Corp. (SMIH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Summit Healthcare Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
- Shardul Securities Limited (SHARDUL.BO) Income Statement Analysis – Financial Results
- Charger Metals NL (CHR.AX) Income Statement Analysis – Financial Results
- Skandinaviska Enskilda Banken AB (publ) (SEB-A.ST) Income Statement Analysis – Financial Results
- Worsley Investors Limited (WINV.L) Income Statement Analysis – Financial Results
- Soulbrain Co., Ltd. (357780.KQ) Income Statement Analysis – Financial Results
Summit Healthcare Acquisition Corp. (SMIH)
Industry: Shell Companies
Sector: Financial Services
About Summit Healthcare Acquisition Corp.
Summit Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Central, Hong Kong.
| Metric | 2021 |
|---|---|
| Revenue | 0.00 |
| Cost of Revenue | 0.00 |
| Gross Profit | 0.00 |
| Gross Profit Ratio | 0.00% |
| Research & Development | 0.00 |
| General & Administrative | 549.18K |
| Selling & Marketing | 0.00 |
| SG&A | 549.18K |
| Other Expenses | -507.42K |
| Operating Expenses | 549.18K |
| Cost & Expenses | 549.18K |
| Interest Income | 7.28K |
| Interest Expense | 0.00 |
| Depreciation & Amortization | -503.59K |
| EBITDA | -549.18K |
| EBITDA Ratio | 0.00% |
| Operating Income | -549.18K |
| Operating Income Ratio | 0.00% |
| Total Other Income/Expenses | 3.45K |
| Income Before Tax | -545.73K |
| Income Before Tax Ratio | 0.00% |
| Income Tax Expense | -7.28K |
| Net Income | -538.45K |
| Net Income Ratio | 0.00% |
| EPS | -0.03 |
| EPS Diluted | -0.03 |
| Weighted Avg Shares Out | 16.93M |
| Weighted Avg Shares Out (Dil) | 16.93M |
EQUITY ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages YS Biopharma Co., Ltd. f/k/a Summit Healthcare Acquisition Corp. Investors to Inquire About Securities Class Action Investigation – YS, SMIH
Source: https://incomestatements.info
Category: Stock Reports